Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Treatment of BRAF(V600E) mutant melanoma by small molecule drugs that target the BRAF or MEK kinases can be effective, but resistance develops invariably. In contrast, colon cancers that harbour the same BRAF(V600E) mutation are intrinsically resistant to BRAF inhibitors, due to feedback activation of the epidermal growth factor receptor (EGFR). Here we show that 6 out of 16 melanoma tumours analysed acquired EGFR expression after the development of resistance to BRAF or MEK inhibitors. Using a chromatin-regulator-focused short hairpin RNA (shRNA) library, we find that suppression of sex determining region Y-box 10 (SOX10) in melanoma causes activation of TGF-β signalling, thus leading to upregulation of EGFR and platelet-derived growth factor receptor-β (PDGFRB), which confer resistance to BRAF and MEK inhibitors. Expression of EGFR in melanoma or treatment with TGF-β results in a slow-growth phenotype with cells displaying hallmarks of oncogene-induced senescence. However, EGFR expression or exposure to TGF-β becomes beneficial for proliferation in the presence of BRAF or MEK inhibitors. In a heterogeneous population of melanoma cells having varying levels of SOX10 suppression, cells with low SOX10 and consequently high EGFR expression are rapidly enriched in the presence of drug, but this is reversed when the drug treatment is discontinued. We find evidence for SOX10 loss and/or activation of TGF-β signalling in 4 of the 6 EGFR-positive drug-resistant melanoma patient samples. Our findings provide a rationale for why some BRAF or MEK inhibitor-resistant melanoma patients may regain sensitivity to these drugs after a 'drug holiday' and identify patients with EGFR-positive melanoma as a group that may benefit from re-treatment after a drug holiday.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, adaptive feedback resistance has been a key limitation in prior clinical efforts to target the RAS-MAPK pathway.”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [32]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For example, RTK-driven feedback reactivation of RAS-MAPK signaling has been identified as a key driver of resistance in BRAFV600E cancers treated with BRAF inhibitors (colorectal cancer in particular) and in KRAS-mutant cancers treated with MEK inhibitors (11,12,32).”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [32]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Multiple studies have demonstrated that in BRAF V600E mutant cancers, BRAF inhibition can lead to rapid EGFR-mediated feedback activation [95,96,104].”
From Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer (2021) · cites this paper as [104]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Self-citationOncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218
Systematic identification of genomic markers of drug sensitivity in cancer cells
Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M.-K., Attar, N., Sazegar, H., et al. (2010) · Nature · doi:10.1038/nature09626 · Cited by 2,192
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M., Demidov, L. V., Hassel, J. C., Rutkowski, P., Mohr, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203421 · Cited by 2,160
Self-citationBRAFE600-associated senescence-like cell cycle arrest of human naevi
Michaloglou, C., Vredeveld, L. C. W., Soengas, M. S., Denoyelle, C., Kuilman, T., van der Horst, C. M. A. M., Majoor, D. M., Shay, J. W., Mooi, W. J., & Peeper, D. S. (2005) · Nature · doi:10.1038/nature03890 · Cited by 2,160
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051
Self-citationCOT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., Emery, C. M., Stransky, N., Cogdill, A. P., Barretina, J., et al. (2010) · Nature · doi:10.1038/nature09627 · Cited by 1,460
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
Poulikakos, P. I., Persaud, Y., Janakiraman, M., Kong, X., Ng, C., Moriceau, G., Shi, H., Atefi, M., Titz, B., Gabay, M. T., et al. (2011) · Nature · doi:10.1038/nature10662 · Cited by 1,454
Cited by
Items 501–600 of 916
Targeting Upregulated cIAP2 in SOX10-Deficient Drug Tolerant Melanoma
Glasheen, M. Q., Caksa, S., Young, A. G., Wilski, N. A., Ott, C. A., Chervoneva, I., Flaherty, K. T., Herlyn, M., Xu, X., Aplin, A. E., et al. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0025 · Cited by 19
Billing, O., Holmgren, Y., Nosek, D., Hedman, H., & Hemmingsson, O. (2021) · Oncogene · doi:10.1038/s41388-021-01808-3 · Cited by 17
Suppression of heparan sulfation re-sensitizes YAP1-driven melanoma to MAPK pathway inhibitors
Dieter, S. M., Lovecchio, D., Pataskar, A., Zowada, M. K., Körner, P.-R., Khalizieva, A., van Tellingen, O., Jäger, D., Glimm, H., & Agami, R. (2022) · Oncogene · doi:10.1038/s41388-022-02400-z · Cited by 18
“EGFR expression has been shown to mediate melanoma resistance toward BRAF inhibitors [22] and not to be beneficial in the absence of Vemurafenib.”
BackgroundPucciarelli, D., Lengger, N., Takáčová, M., Csáderová, L., Bartošová, M., Breiteneder, H., Pastoreková, S., & Häfner, C. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3010 · Cited by 16
“However, incomplete response and acquired drug resistance caused by multiple abnormally regulated signaling pathways present in melanoma frequently led to treatment failures and tumor progression (8-10).”
BackgroundWINDOW consortium: A path towards increased therapy efficacy against glioblastoma
Abdul, K., Houweling, M., Svensson, F., Narayan, R. S., Cornelissen, F. M. G., Küçükosmanoğlu, A., Metzakopian, E., Watts, C., Bailey, D. S., Würdinger, T., et al. (2018) · Drug Resistance Updates · doi:10.1016/j.drup.2018.10.001 · Cited by 20
The cancer cell proteome and transcriptome predicts sensitivity to targeted and cytotoxic drugs
Rydenfelt, M., Wongchenko, M. J., Klinger, B., Yan, Y., & Blüthgen, N. (2019) · Life Science Alliance · doi:10.26508/lsa.201900445 · Cited by 17
“Among the resistance markers to MAPK inhibitors, high expression of EGFR, which is normally expressed in very low levels in melanoma, is a known resistance mechanism to counteract BRAF and MEK inhibitors (Klinger & Blüthgen, 2014; Sun et al, 2014).”
Combined BRAF, MEK, and heat‐shock protein 90 inhibition in advanced BRAF V600‐mutant melanoma
Eroglu, Z., Chen, Y. A., Smalley, I., Li, J., Markowitz, J., Brohl, A. S., Tetteh, L. F., Taylor, H., Sondak, V. K., Khushalani, N. I., et al. (2023) · Cancer · doi:10.1002/cncr.35029 · Cited by 16
Du, Z., Zhang, T., Lin, Y., Guifen, D. O. N. G., Li, A., Wang, Z., Zhang, Y. J., Giamas, G., Stebbing, J., Zhu, L., et al. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e20708 · Cited by 15
“…fission, chromosome segregation, mitotic nuclear division, positive regulation of cell cycle, and DNA replication, etc., which is consistent with previous studies demonstrating that the mitogenic and survival pathways are related to cells with slow-proliferating drug-tolerant phenotypes [9].”
ResultClonal differences underlie variable responses to sequential and prolonged treatment
Schaff, D. L., Fasse, A. J., White, P. E., Velde, R. V., & Shaffer, S. M. (2024) · Cell Systems · doi:10.1016/j.cels.2024.01.011 · Cited by 16
Role and Function of Receptor Tyrosine Kinases in BRAF Mutant Cancers
Biersack, B., Tahtamouni, L. H., & Höpfner, M. (2024) · Receptors · doi:10.3390/receptors3010005 · Cited by 17
“Suppression of the SOX family transcription factor SOX10 (sex-determining region Y-box 10) induced TGF-β signaling, followed by activation of EGFR in BRAF inhibitor-resistant melanomas [109].”
BackgroundHároníková, L., Zatloukalová, P., Kucerikova, M., Friedlová, N., Tylichová, Z., Kokas, F. Z., Hupp, T. R., Coates, P. J., & Vojtěšek, B. (2024) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-024-00637-y · Cited by 18
Tate, S. C., Burke, T. F., Hartman, D. G., Kulanthaivel, P., Beckmann, R. P., & Cronier, D. M. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.40 · Cited by 16
“…that vemurafenib resistance is reversible: altered EGFR expression levels as a result of vemurafenib treatment are counterselected in its absence (Sun et al., 2014), intermittent dosing delays tumour progression in preclinical models of BRAF-mutated melanoma (Das Thakur et al., 2013; Abdel-Wahab…”
BackgroundRizzolio, S., Corso, S., Giordano, S., & Tamagnone, L. (2020) · Cancers · doi:10.3390/cancers12082218 · Cited by 16
“EGFR kinase activity was actually found to mediate adaptive drug resistance in melanoma cells [6,7].”
BackgroundGZ17-6.02 Interacts With [MEK1/2 and B-RAF Inhibitors] to Kill Melanoma Cells
Booth, L. A., West, C. E., Hoff, D. D. V., Kirkwood, J. M., & Dent, P. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.656453 · Cited by 16
Mundra, V., Peng, Y., Kumar, V., Li, W., Miller, D. D., & Mahato, R. I. (2015) · Drug Delivery and Translational Research · doi:10.1007/s13346-015-0226-2 · Cited by 18
“DTIC, an alkylating agent, exhibits modest efficacy and does not significantly prolong the survival benefit [2] (less than 5 % complete remission), whereas resistance develops invariably upon treatment with kinase inhibitors which restricts the prolonged systemic therapy with these inhibitors [3, 4].”
REPOSIT study group, van der Hiel, B., Haanen, J. B. A. G., Stokkel, M. P. M., Peeper, D. S., Jiménez, C. R., Beijnen, J. H., van de Wiel, B. A., Boellaard, R., & van den Eertwegh, A. J. M. (2017) · BMC Cancer · doi:10.1186/s12885-017-3626-5 · Cited by 15
“Other mechanisms, not involving the MAPK-pathway, have been found as well, like upregulation of IGF-1R, EGFR, PDGFR β , FOXP3 or FGFR3 signaling [43 – 45].”
Self-citationViñal, D., Martínez, D., & Espinosa, E. (2019) · Clinical & Translational Oncology · doi:10.1007/s12094-018-02028-0 · Cited by 15
Resistance to Targeted Therapy and RASSF1A Loss in Melanoma: What Are We Missing?
McKenna, S., & García-Gutiérrez, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105115 · Cited by 16
“SOX10 Low levels Increased RTK − + + [57]”
BackgroundLee, W.-R., Shen, S., Shih, Y., Chou, C., Tseng, J. T.-P., Chin, S., Liu, K.-H., Chen, Y., & Jiang, M. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0553-6 · Cited by 16
Tumor-initiating CD49f cells are a hallmark of chemoresistant triple negative breast cancer
Miragaya, J. G., & González‐Suárez, E. (2017) · Molecular & Cellular Oncology · doi:10.1080/23723556.2017.1338208 · Cited by 15
Real-time feedback control microscopy for automation of optogenetic targetingPreprint
Hinderling, L., Landolt, A. E., Grädel, B., Dubied, L., Zahni, C., Kwasny, M., Bassi, D., Frismantiene, A., Lambert, T., Dobrzyński, M., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.17.670729 · Cited by 14
Yang, H., Xiao, X., Zeng, L., Zeng, H., Zheng, Y., Wang, J., Li, G., Dai, W., He, Y., Wang, S., et al. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-023-04675-6 · Cited by 18
“Furthermore, liquid biopsy of BRAF V600E mutation can be suggestive of resistance after melanoma patient receiving Vemurafenib treatment [9].”
BackgroundAnaya, Y. A., Bracho, R. P., Chauhan, S. C., Tripathi, M. K., & Bandyopadhyay, D. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062676 · Cited by 14
“This suggests that tumors may evade B-RAF inhibition by upregulating EGFR, leading to sustained MAPK pathway activation and enhanced metastatic potential [26].”
Fibroblasts Influence Metastatic Melanoma Cell Sensitivity to Combined BRAF and MEK Inhibition
Morales, D., Vigneron, P., Ferreira, I. G., Hamitou, W., Magnano, M., Mahenthiran, L., Lok, C., & Vayssade, M. (2021) · Cancers · doi:10.3390/cancers13194761 · Cited by 15
“However, some patients with the BRAF mutation either do not respond to treatment (approximately 10 to 20%) [5–7] or develop resistance, very often within a median time of 6 months after starting treatment [8].”
BackgroundThe epigenome and the many facets of cancer drug tolerance
Moore, P. C., Henderson, K. W., & Classon, M. (2023) · Advances in cancer research · doi:10.1016/bs.acr.2022.12.002 · Cited by 15
Localized immune surveillance of primary melanoma in the skin deciphered through executable modeling
Howell, R. S. M., Davies, J., Clarke, M. A., Appios, A., Mesquita, I., Jayal, Y., Ringham-Terry, B., del Río, I. B., Fisher, J., & Bennett, C. L. (2023) · Science Advances · doi:10.1126/sciadv.add1992 · Cited by 15
A step forward on the in vitro and in vivo assessment of a novel nanomedicine against melanoma
Pinho, J. O., Matias, M., Godinho‐Santos, A., Amaral, J. D., Mendes, E., Perry, M. D. J., Francisco, A. P., Rodrigues, C. M. P., & Gaspar, M. M. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.123011 · Cited by 14
Su, Y., Liu, C., Lu, X., Chuang, H.-Y., Li, G., Shao, S., Kong, Y., Lee, J. W., Ng, R. H., Wong, S., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-71349-4 · Cited by 14
“While previous reports claimed a reversible process for adaptive dedifferentiation transition in melanoma 5,10,15 , our more granular data set revealed a cyclic loop comprised of forward (blue) and reverse (green) trajectories that did not overlap, with two gene modules operating sequentially…”
InfluentialSuppression of B-Raf(V600E) cancers by MAPK hyper-activation
Atiq, R., Hertz, R., Eldad, S., Smeir, E., & Bar‐Tana, J. (2016) · Oncotarget · doi:10.18632/oncotarget.7909 · Cited by 14
“Growth inhibition by hyper-activated Erk may also account for the recently proposed “drug holiday” treatment protocol for resistant B-Raf(V600E) tumors [36, 37], whereby intermittent elimination of the B-Raf(V600E) kinase inhibitor may result in Erk hyperactivation leading to transient suppression of resistant targets.”
BackgroundSzász, I., Koroknai, V., Kiss, T., Vízkeleti, L., Ádány, R., & Balázs, M. (2019) · Melanoma Research · doi:10.1097/cmr.0000000000000588 · Cited by 14
The mechanism of cancer drug addiction in ALK-positive T-Cell lymphoma
Rajan, S. S., Amin, A. D., Li, L., Rolland, D. C. M., Li, H., Kwon, D., Kweh, M. F., Arumov, A., Roberts, E. R., Yan, A., et al. (2019) · Oncogene · doi:10.1038/s41388-019-1136-4 · Cited by 14
Extracellular Matrix Remodeling in Intestinal Homeostasis and Disease
Lee, S.-E., Massie, I., Meran, L., & Li, V. S. W. (2018) · Advances in stem cells and their niches · doi:10.1016/bs.asn.2018.01.001 · Cited by 16
Acciardo, S., Mignion, L., Lacomblez, E., Schoonjans, C. A., Joudiou, N., Gourgue, F., Bouzin, C., Baurain, J., Gallez, B., & Jordan, B. F. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14890 · Cited by 15
Langdon, C. G., Held, M. A., Platt, J. T., Meeth, K. M., Iyidogan, P., Mamillapalli, R., Koo, A. B., Klein, M., Liu, Z. Z., Bosenberg, M., et al. (2015) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12376 · Cited by 13
“RTKs that cause adaptive resistance to BRAF and MEK inhibitors include AXL, EGFR, ERBB3, and PDGFRb (Abel et al., 2013; Kugel and Aplin, 2014; Muller et al., 2014; Rebecca et al., 2014; Shi et al., 2011; Sun et al., 2014).”
BackgroundEmbaby, A., Huijberts, S. C. F. A., Wang, L., de Oliveira, R. L., Rosing, H., Nuijen, B., Sanders, J., Hofland, I., van Steenis, C., Kluin, R. J. C., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3171 · Cited by 15
Self-citationKot, M., Simiczyjew, A., Wądzyńska, J., Ziętek, M., Matkowski, R., & Nowak, D. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01788-3 · Cited by 14
“Its overexpression was observed in 6 of 16 biopsies derived from patients with BRAFi/MEKi-resistant melanomas and may be associated with elevated invasiveness of melanoma cells [54].”
BackgroundSOX10 mediates glioblastoma cell-state plasticity
Man, K.-H., Wu, Y., Gao, Z., Spreng, A., Keding, J., Mangei, J., Boskovic, P., Mallm, J., Liu, H., Imbusch, C. D., et al. (2024) · EMBO Reports · doi:10.1038/s44319-024-00258-8 · Cited by 15
“Our results are corroborated by fi ndings suggesting an association between treatment-induced SOX10 expression and a slow-cycling phenotype in both glioma and melanoma (Capparelli et al, 2022; Cronin et al, 2013; Lau et al, 2015; Sun et al, 2014).”
The roles of cancer stem cells and therapeutic implications in melanoma
Mu, X., Zhou, Y., Yu, Y., Zhang, M., & Liu, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1486680 · Cited by 14
“This, in turn, contributes to resistance against BRAF and MEK inhibition by bestowing survival signals that are independent of the MAPK pathway (54).”
TGFβ signaling sensitizes MEKi-resistant human melanoma to targeted therapy-induced apoptosis
Loos, B., Salas-Bastos, A., Nordin, A., Debbache, J., Stierli, S., Cheng, P. F., Rufli, S., Wyss, C., Levesque, M. P., Dummer, R., et al. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-07305-1 · Cited by 14
Mukherjee, U., Hockings, H., Counsell, N., Patel, A., Narayanan, P., Wilkinson, K., Dhanda, H. K., Robinson, K., McNeish, I. A., Anderson, A. R. A., et al. (2024) · BMJ Open · doi:10.1136/bmjopen-2024-091262 · Cited by 16
Role of exosomes in transforming growth factor-β-mediated cancer cell plasticity and drug resistance
Ruksha, T. G., & Palkina, N. V. (2025) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2025.1002322 · Cited by 16
SMAD-oncoprotein interplay: Potential determining factors in targeted therapies
Li, X., & Feng, X. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114155 · Cited by 13
Can Systems Biology Advance Clinical Precision Oncology?
Rocca, A., & Kholodenko, B. Ν. (2021) · Cancers · doi:10.3390/cancers13246312 · Cited by 16
M-CSF as a therapeutic target in BRAFV600E melanoma resistant to BRAF inhibitors
Barceló, C., Sisó, P., de la Rosa, I., Megino‐Luque, C., Navaridas, R., Maiques, Ó., Urdanibia, I., Eritja, N., Soria, X., Potrony, M., et al. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01886-4 · Cited by 14
“All the data support the idea that autophagy inhibition along with M-CSF mAb, as a therapyinhibiting tumour secretome, may offer a promising new strategy to deal with resistant mechanisms in melanoma cells [9, 10, 18, 51].”
BackgroundEpistasis and evolutionary dependencies in human cancers
Mina, M., Iyer, A., & Ciriello, G. (2022) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2022.101989 · Cited by 14
Epigenetic adaptations in drug-tolerant tumor cells
Mani, N., Daiya, A., Chowdhury, R., Mukherjee, S., & Chowdhury, S. (2023) · Advances in cancer research · doi:10.1016/bs.acr.2022.12.006 · Cited by 15
Nrf2 as a Therapeutic Target in the Resistance to Targeted Therapies in Melanoma
Cucci, M. A., Grattarola, M., Monge, C., Roetto, A., Barrera, G., Caputo, E., Dianzani, C., & Pizzimenti, S. (2023) · Antioxidants · doi:10.3390/antiox12061313 · Cited by 17
“Since the resistance to targeted therapies in melanoma can be reversible and adaptive [41], the resistant cells were kept under drug-selective pressure.”
BackgroundMa, Z.-R., Xiong, Q., Cai, S., Ding, L., Yin, C.-H., Xia, H., Liu, W., Dai, S., Zhang, Y., Zhu, Z.-H., et al. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110617 · Cited by 13
RICTOR/mTORC2 downregulation in BRAFV600E melanoma cells promotes resistance to BRAF/MEK inhibition
Ponzone, L., Audrito, V., Landi, C., Moiso, E., Levron, C. L., Ferrua, S., Savino, A., Vitale, N., Gasparrini, M., Avalle, L., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02010-1 · Cited by 16
Trametinib in metastatic melanoma
Chopra, N., & Nathan, P. (2015) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2015.1060127 · Cited by 14
“Non-genetic causes include truncations in the BRAF protein through alternative splicing leading to increased dimerization and kinase activity [40], upregulation of bypass pathways mediated by MAP3K8 [41], CRAF and IGF-R overexpression [42,43], upregulation of EGFR and PDGFRb [44,45] and alterations in MAPK pathway and…”
BackgroundSilencing TCF4 Sensitizes Melanoma Cells to Vemurafenib Through Inhibiting GLUT3-Mediated Glycolysis
Liu, C., He, S., Zhang, J., Li, S., Chen, J., & Han, C. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s245531 · Cited by 15
Zhu, E. Y., Riordan, J. D., Vanneste, M., Henry, M. D., Stipp, C. S., & Dupuy, A. J. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00310-7 · Cited by 14
Decoding transcriptional states in cancer
Wouters, J., Atak, Z. K., & Aerts, S. (2017) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2017.01.003 · Cited by 13
Huang, S., Deng, W., Wang, P., Yan, Y., Xie, C., Cao, X., Chen, M., Zhang, C., Shi, D., Dong, Y., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01954-8 · Cited by 13
Self-citationRetractedPrecision Immunology: The Promise of Immunotherapy for the Treatment of Cancer
Kaufman, H. L. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.6023 · Cited by 17
Molecular Susceptibility and Treatment Challenges in Melanoma
Shenoy, P. V., Nag, R., Kolathur, K. K., Malik, Y., Varanasi, S. M., Angom, R. S., & Mukhopadhyay, D. (2024) · Cells · doi:10.3390/cells13161383 · Cited by 12
Smith, G. T., Radin, D. P., & Tsirka, S. E. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.958620 · Cited by 13
“While one avenue of targeting melanoma involved inhibiting the BRAF kinase, drug resistance ensued from BRAF-addicted cancer cells, mediated through downregulation of sexdetermining region Y-related high mobility group box 10 protein (SOX10) via miRNA-338, which was associated with Nrp1 expression in melanoma (91).”
BackgroundSabbah, M., Najem, A., Vanderkerkhove, C., Kert, F., Jourani, Y., Journé, F., Awada, A. H., Gestel, D. V., Ghanem, G., & Krayem, M. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1149918 · Cited by 12
“Several consecutive findings of our work support a c-Met role in melanoma radioresistance through its association and activation of PARP-1: (1) c-Met specific inhibition or KO alike radiosensitizes melanoma cells by affecting cell proliferation and increasing cell death; (2) RT promotes c-Met translocation to the peri…”
BackgroundVergoulidou, M. (2015) · Biomarker Insights · doi:10.4137/bmi.s22436 · Cited by 15
BRAF and MEK inhibitor therapy eliminates Nestin‐expressing melanoma cells in human tumors
Doxie, D. B., Greenplate, A. R., Gandelman, J. S., Diggins, K. E., Roe, C. E., Dahlman, K. B., Sosman, J. A., Kelley, M. C., & Irish, J. M. (2018) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12712 · Cited by 13
Louveau, B., Jouenne, F., de Moura, C. R., Sadoux, A., Baroudjian, B., Delyon, J., Herms, F., de Masson, A., Meda, L. D., Battistella, M., et al. (2019) · Cancers · doi:10.3390/cancers11081203 · Cited by 12
Integrin αvβ3‐Akt signalling plays a role in radioresistance of melanoma
Im, H., Lee, J., Ryu, K., & Yi, J. Y. (2020) · Experimental Dermatology · doi:10.1111/exd.14102 · Cited by 12
Rapid Noninvasive Skin Monitoring by Surface Mass Recording and Data Learning
Zhu, Y., Lesch, A. S., Li, X. N., Lin, T., Gasilova, N., Jović, M., Pick, H. M., Ho, P., & Girault, H. H. (2021) · JACS Au · doi:10.1021/jacsau.0c00074 · Cited by 12
Oncolytic Virotherapy for Melanoma Brain Metastases, a Potential New Treatment Paradigm?
Soldozy, S., Mulligan, K. M., Zheng, D. X., Levoska, M. A., Cullison, C. R., Elarjani, T., Eichberg, D. G., Ampie, L., Shah, A. H., Yağmurlu, K., et al. (2021) · Brain Sciences · doi:10.3390/brainsci11101260 · Cited by 12
“Up to 95% of BRAF-mutant melanomas have the V600E mutation, which confers an approximately 12% increased risk of brain metastases compared to wildtype patients [7,8].”
BackgroundYue, Z., Sun, J., & Shi, L. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.887542 · Cited by 14
“Notably, high expression of EGFR results in a slow-growth phenotype with melanoma cells (Sun et al., 2014), but EGFR turned into a cancer-promoting factor and contributed to the targeted therapy resistance to BRAF or MEK inhibitors (Quadri et al.”
BackgroundEschbach, R., Kazmierczak, P. M., Heimer, M. M., Todica, A. S., Hirner-Eppeneder, H., Schneider, M. J., Keinrath, G., Solyanik, O., Olivier, J., Kunz, W. G., et al. (2018) · Cancer Imaging · doi:10.1186/s40644-018-0135-y · Cited by 13
Yu, L., Fan, P., Dong, X., Chen, Y., Sun, D., Jiang, S., & Deng, C. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.564740 · Cited by 14
“Moreover, Sun et al. (2014) demonstrated that SOX10 can inhibit the activation of transforming growth factor (TGF) scaffold signaling in melanoma cells and promote resistance to BRAF and mitogen-activated protein kinase (MAPK) and extracellular Frontiers in Cell and Developmental Biology |…”
BackgroundTargeted Therapy Innovations for Melanoma
Amarillo, D., Flaherty, K. T., & Sullivan, R. J. (2024) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2024.05.006 · Cited by 11
Intermittent BRAF Inhibition Can Achieve Prolonged Disease Control in BRAF Mutant Melanoma
Jain, T., & Bryce, A. H. (2015) · Cureus · doi:10.7759/cureus.410 · Cited by 11
“This EGFR expression was beneficial for proliferation to melanoma cells in the presence of BRAF or MEK inhibitors, and this is reversed upon discontinuation of the drug [6].”
BackgroundClaas, A., Atta, L., Gordonov, S., Meyer, A. S., & Lauffenburger, D. A. (2018) · Cellular and Molecular Bioengineering · doi:10.1007/s12195-018-0542-y · Cited by 14
Melanoma Single-Cell Biology in Experimental and Clinical Settings
Binder, H., Schmidt, M., Loeffler‐Wirth, H., Mortensen, L. S., & Kunz, M. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10030506 · Cited by 11
“BRAF-mutant melanomas may also acquire resistance through activation of the EGFR pathway, as shown in a study on melanoma patients treated with vemurafenib or dabrafenib, a finding that has been observed earlier in colon cancer [19].”
BackgroundHarbers, F. N., Thier, B., Stupia, S., Zhu, S., Schwamborn, M., Peller, V., Chauvistré, H., Crivello, P., Fleischhauer, K., Roesch, A., et al. (2021) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2021.03.013 · Cited by 12
Clinical evaluation of BCL-2/XL levels pre- and post- HER2-targeted therapy
Zoeller, J. J., Press, M. F., Selfors, L. M., Dering, J., Slamon, D. J., Hurvitz, S. A., & Brugge, J. S. (2021) · PLoS ONE · doi:10.1371/journal.pone.0251163 · Cited by 12
“Treatment-associated adaptive reprograming often includes parallel upregulation of alternative receptors and/or activation of alternative pathways, which compensate for target inhibition and maintain tumor growth and survival (2-8).”
BackgroundCelesia, A., Notaro, A., Franzò, M., Lauricella, M., D’Anneo, A., Carlisi, D., Giuliano, M., & Emanuele, S. (2022) · Biomedicines · doi:10.3390/biomedicines10081994 · Cited by 12
Comparative Network Reconstruction using mixed integer programming
Bosdriesz, E., Prahallad, A., Klinger, B., Sieber, A., Bosma, A. R., Bernards, R., Blüthgen, N., & Wessels, L. F. A. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty616 · Cited by 11
Self-citationUtility of Sry‐Related HMG‐Box Gene 10 (SOX10) as a marker of melanoma in effusion cytology
Dermawan, J. K. T. K., Underwood, D. L., & Policarpio‐Nicolas, M. L. (2019) · Diagnostic Cytopathology · doi:10.1002/dc.24162 · Cited by 11
Milewska, M., Romano, D., Herrero, A., Guerriero, M. L., Birtwistle, M. R., Quehenberger, F., Hatzl, S., Kholodenko, B. Ν., Segatto, O., Kölch, W., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0129859 · Cited by 12
“In recent studies of thyroid carcinoma and melanoma, SPRY2 and SOX10 have been identified as additional BRAF-EGFR feedback mediators, which suggests that feedback signaling of BRAF V600E to the EGFR might be more complex than initially thought and includes other, hitherto unknown proteins as well [7, 8].”
BackgroundCancer Stem Cells in Melanoma: Drivers of Tumor Plasticity and Emerging Therapeutic Strategies
Sabău, A.-H., Tinca, A. C., Niculescu, R., Cocuz, I. G., Cozac-Szőke, A. R., Lazar, B. A., Chiorean, D. M., Budin, C. E., & Cotoi, O. S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157419 · Cited by 10
“Incomplete elimination of these cells during treatments (chemotherapy, targeted therapies, or immunotherapy) leads to therapeutic failure and disease progression [71,72].”
McGonagle, E. R., & Nucera, C. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00468 · Cited by 10
Ren, M., Wang, L., Deng, X., Gao, Z.-X., Wang, Q., Tao, M., Shen, K., Ding, Y.-T., Qian, L., Wei, C., et al. (2022) · Bioengineered · doi:10.1080/21655979.2022.2080385 · Cited by 10
Self-citationRetractedMcl-1 mediates intrinsic resistance to RAF inhibitors in mutant BRAF papillary thyroid carcinoma
Cavallo, M. R., Yo, J., Gallant, K. C., Cunanan, C. J., Amirfallah, A., Daniali, M., Sanders, A. B., Aplin, A. E., Pribitkin, E. A., & Hartsough, E. J. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-01945-0 · Cited by 10
“In many cases, drug treatment effectively shrinks tumors; however, a subset of tumor cells employ adaptive resistance – cellular programming that quickly responds to ERK1/2 inhibition to promote survival [13, 14].”
Deciphering TGF-β1's role in drug resistance and leveraging plant bioactives for cancer therapy
Deb, V. K., Chauhan, N., & Jain, U. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.177218 · Cited by 10
Bai, J., Wan, Z., Zhou, W., Wang, L., Lou, W., Zhang, Y., & Jin, H. (2025) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2025.1538743 · Cited by 10
Self-citationNath, K., NELSON, D. S., Putt, M., Leeper, D. B., Garman, B., Nathanson, K. L., & Glickson, J. D. (2016) · PLoS ONE · doi:10.1371/journal.pone.0157125 · Cited by 10
“Development of resistance following oncogene inhibition is common in the clinic, where tumor cells acquire or develop pro-survival mechanisms to maintain their growth [59, 60].”
BackgroundMany Distinct Ways Lead to Drug Resistance in BRAF- and NRAS-Mutated Melanomas
Vachtenheim, J., & Ondrušová, Ľ. (2021) · Life · doi:10.3390/life11050424 · Cited by 10
The Elongin BC Complex Negatively Regulates AXL and Marks a Differentiated Phenotype in Melanoma
Schieven, S. M., Traets, J. J. H., Vliet, A. V., Baalen, M. V., Song, J., Guimaraes, M. D. S., Kuilman, T., & Peeper, D. S. (2023) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-22-0648 · Cited by 10
Sequencing and curation strategies for identifying candidate glioblastoma treatments
Frank, M. O., Koyama, T., Rhrissorrakrai, K., Robine, N., Utro, F., Emde, A., Chen, B., Arora, K. S., Shah, M. J., Geiger, H. M., et al. (2019) · BMC Medical Genomics · doi:10.1186/s12920-019-0500-0 · Cited by 10
Phylogenetic Quantification of Intratumor Heterogeneity
Watkins, T. B. K., & Schwarz, R. F. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a028316 · Cited by 10
“For example, BRAF or MEK inhibitors for metastatic melanoma trigger impressive initial responses, but invari- ably the cancer develops resistance to the targeted treatment (Sun et al. 2014).”
BackgroundLuan, W., Xu, L., Peng, H., Shen, X., Rao, M., & Ruan, H. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155410 · Cited by 9
The KLF16/MYC feedback loop is a therapeutic target in bladder cancer
Zheng, L., Wang, J., Han, S., Zhong, L., Liu, Z., Li, B., Zhang, R., Zhou, L., Zheng, X. F. S., Liu, Z., et al. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03224-3 · Cited by 10
“Subsequently, the sequence of the KLF16 promoter was analyzed, and we found two consensus E-box sequences (CAC GTG ), designated as MYC binding sites 1 and 2 (MBS1/2), along with a similar E-box site (ACC GTG ), referred to as MYC binding site 3 (MBS3).”
Self-citationChung, J., Ramani, V., Guo, L., Popat, V., Cruz, P. D., Xu, L., Hammers, H. J., & Ariizumi, K. (2025) · Communications Medicine · doi:10.1038/s43856-025-00786-x · Cited by 10
“SOX10 gene expression confers AR to BRAF inhibitors (BRAFi) 78 .”
Saintas, E., Abrahams, L., Ahmad, G. T., Ajakaiye, A.-O. M., AlHumaidi, A. S. H. A. M., Ashmore‐Harris, C., Clark, I. C., Dura, U. K., Fixmer, C. N., Ike-Morris, C., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0172140 · Cited by 10
Chromatin assembly factor 1 suppresses epigenetic reprogramming toward adaptive drug resistance
Wang, Z., Wu, R., Nie, Q., Bouchonville, K. J., Diasio, R. B., & Offer, S. M. (2021) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2020.12.003 · Cited by 10
“Transcriptional analysis by RNA sequencing (RNA-seq) showed dramatic changes in gene expression (Supplementary Fig.1e), with resistant cells showing significantly altered expression of genes associated with BRAFi resistance 6, 9, 22 (Supplementary Fig.”
BackgroundCytoskeletal Remodelling as an Achilles’ Heel for Therapy Resistance in Melanoma
Barreno, A., & Orgaz, J. L. (2022) · Cells · doi:10.3390/cells11030518 · Cited by 9
“Regarding the resistant state, most resistant tumours (≈70%) display a MAPK pathway reactivation through a variety of mechanisms [16]: (1) drug targeted alterations through genetic mechanisms (BRAF amplification [49,50]) and alternative splicing [51]; (2) hyperactivation of compensatory signalling pathways (FAK [52],…”
BackgroundTGF-β Signaling Activation Confers Anlotinib Resistance in Gastric Cancer
Chen, J., Hai, Y., Hu, Q., Chen, C., Jiang, X.-H., & Gao, Y. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03461-1 · Cited by 9
“TGF-β pathway activated by inhibition of SRYbox transcription factor 10 (SOX10) could upregulate EGFR and PDGFR-β signaling and thereby resulted in drug resistance to MAPK inhibitors [33].”
BackgroundGeneration of Myeloid-Derived Suppressor Cells Mediated by MicroRNA-125a-5p in Melanoma
Lasser, S., Kurt, F. G. Ö., Fritz, L., Gutzeit, N., Torre, C. D. L., Altevogt, P., Utikal, J. S., & Umansky, V. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126693 · Cited by 10
Lei, J., Liu, Y., & Fan, Y. (2024) · Neurosurgical Review · doi:10.1007/s10143-024-02664-x · Cited by 9
Navigating Nongenetic Plasticity in Cancer Drug Resistance
Sun, H., Kumari, N., Melzer, M. E., Backman, V., & Goyal, Y. (2024) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-071924-084617 · Cited by 12
Application of adoptive cell therapy in malignant melanoma
Hu, Q., Xuan, J., Wang, L., Shen, K., Gao, Z., Zhou, Y., Wei, C., & Gu, J. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06093-2 · Cited by 9
“However, low response rates and resistance can still occur, even with combination therapy, due to the loss of SOX10 expression and suppressive tumor microenvironment (TME) [14–16].”
Self-citationHe, W., McCoy, M., Riggins, R. B., Beckman, R. A., & Yeang, C. (2025) · npj Systems Biology and Applications · doi:10.1038/s41540-025-00547-5 · Cited by 14
Metadata
- Authors
- Sun, C., Wang, L., Huang, S., Heynen, G. J. J. E., Prahallad, A., Robert, C., Haanen, J., Blank, C., Wesseling, J., Willems, S. M., Zecchin, D., Hobor, S., Bajpe, P. K., Lieftink, C., Mateus, C., Vagner, S., Grernrum, W., Hofland, I., Schlicker, A., Wessels, L. F. A., Beijersbergen, R. L., Bardelli, A., Di Nicolantonio, F., Eggermont, A. M. M., & Bernards, R.
- Affiliations
- The Netherlands Cancer Institute (NL)
- Institut Gustave Roussy (FR)
- Candiolo Cancer Institute (IT)
- IFOM (IT)
- ORCID
- Sun, Chong
- Wang, Liqin
- Huang, Sidong
- Heynen, Guus J. J. E.
- Prahallad, Anirudh
- Robert, Caroline
- Haanen, John
- Blank, Christian
- Wesseling, Jelle
- Willems, Stefan M.
- Zecchin, Davide
- Lieftink, Cor
- Hofland, Ingrid
- Schlicker, Andreas
- Wessels, Lodewyk F. A.
- Beijersbergen, Roderick L.
- Bardelli, Alberto
- Eggermont, Alexander M. M.
- Venue
- Nature
- Published
- 2014-03-26
- Volume
- 508
- Issue
- 7494
- Pages
- 118-122
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1985928174
- Cited by
- 888
- References
- 30
- Citations by year
- 2026: 29 · 2025: 43 · 2024: 62 · 2023: 58 · 2022: 90 · 2021: 81 · 2020: 71 · 2019: 76 · 2018: 75 · 2017: 83 · 2016: 71 · 2015: 107 · 2014: 39
- FWCI
- 40.97
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- other-oa
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- RePEc: Research Papers in Economics (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Funders
- Canadian Institutes of Health Research (MOP130540)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- BRAF inhibitor resistance, SOX10, TGF-beta signaling, PDGFRβ, oncogene-induced senescence, drug holidays, MEK inhibitors, adaptive resistance, shRNA screen, cell proliferation, tumor heterogeneity, drug re-sensitization, receptor tyrosine kinase
- MeSH terms
- Vemurafenib, Animals, Antineoplastic Agents, Female, Flow Cytometry, Humans, Indoles, Melanoma, Sulfonamides, Signal Transduction, Gene Library, Gene Expression Regulation, Neoplastic, Transforming Growth Factor beta, Cellular Senescence, Drug Resistance, Neoplasm, Receptor Protein-Tyrosine Kinases, Receptor, Platelet-Derived Growth Factor beta, Mitogen-Activated Protein Kinase Kinases, RNA, Small Interfering, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf, Cell Proliferation, Mice, SOXE Transcription Factors, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.